Surgical treatment of congenital heart disease with Eisenmenger syndrome

Ulugbek Mazhidov 1, Rakhima Mekenbayeva 1 * , Yerbol Aldabergenov 1
More Detail
1 Pediatric Cardiac Surgery Department, National Scientific Medical Center, Nur-Sultan city, Republic of Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 18, Issue 1, pp. 14-18. https://doi.org/10.23950/jcmk/9660
OPEN ACCESS 1667 Views 3110 Downloads
Download Full Text (PDF)

ABSTRACT

Article provides review of the available world literature on performing surgical correction of the atrioventricular septal defect (AVSD) in patients with Eisenmenger syndrome such as: basic pathophysiological principles, technique, indications, clinical and hemodynamic results. Currently, according to the literature, there is no clarity in the choice of a method for correcting severe congenital heart defects in combination with Eisenmenger syndrome (one - or two-step approach). The article presents the results of studies of both one-and two-stage approaches to correction of  the atrioventricular septal defect (AVSD) in this category of patients with their advantages and disadvantages.
Keywords: atrioventricular septal defect, pulmonary hypertension, Eisenmenger syndrome, Down syndrome.

CITATION

Mazhidov U, Mekenbayeva R, Aldabergenov Y. Surgical treatment of congenital heart disease with Eisenmenger syndrome. J CLIN MED KAZ. 2021;18(1):14-8. https://doi.org/10.23950/jcmk/9660

REFERENCES

  • Eisenmenger V. Die angeborenen Defecte der Kammer scheidewand des Herzens. Z Klin Med. 1897; 32:1-28.
  • Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004; 43(12):5-12. https://doi.org/10.1016/j.jacc.2004.02.037
  • Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. I. BrMedJ. 1958; 2:701-709 https://doi.org/10.1136/bmj.2.5098.701
  • Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007; 115(8):1039-1050 https://doi.org/10.1161/CIRCULATIONAHA.105.592386
  • Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2009; 54(1):43-54. https: // doi.org/10.1016/j.jacc.2009.04.012
  • Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. BMJ. 1958; 2(5098):701-709 https://doi.org/10.1136/bmj.2.5098.701
  • The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br Med J. 1958; 2(5099):755-62 https://doi.org/10.1136/bmj.2.5099.755
  • Kidd L, Driscoll DJ, Gersony WM, Hayes CJ, Keane JF, O'Fallon WM, et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. Circulation. 1993; 87(2):I38-I51.
  • Berman EB, Barst RJ. Eisenmenger's syndrome: current management. ProgCardiovascDi.s. 2002; 45(2):129-138. https://doi.org/10.1053/pcad.2002.127492
  • Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med. 1998; 128(9):745-755 https://doi.org/10.7326/0003-4819-128-9-199805010-00008
  • Humbert M, Morrell N.W., Archer S.L., Stenmark K.R., MacLean M.R., Lang I.M. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J.Am.Coll.Cardiol. 2004; 43(S):13-24
  • Maurice Beghetti, NazzarenoGaliè. Eisenmenger Syndrome. A Clinical Perspective in a New Therapeutic Era of Pulmonary Arterial Hypertension, J. Am. Coll. Cardiol. 2009; 53(9):733-740.
  • Hartway S. A parent's guide to the genetics of Down syndrome. Adv Neonatal Care. 2009; 9(1):27-30 https://doi.org/10.1097/01.ANC.0000346092.50981.c0
  • Ranweiler R. Assessment and care of the newborn with Down syndrome. Adv Neonatal Care. 2009; 9(1):17-24; Quiz 25-6. https://doi.org/10.1097/01.ANC.0000346090.05240.ab
  • Lamb N.E., Feingold E., Savage A., Avramopoulos D., Freeman S. Characterization of susceptible chaisma configuration that increases the risk for maternal non-disjunction of chromosome 21. Human Molecular Genetics. 1997; 6:1391-1399. https://doi.org/10.1093/hmg/6.9.1391
  • Holland A.J., Cleveland D.W. (June 2012). «Losing balance: the origin and impact of aneuploidy in cancer». EMBO Rep. 13(6):501-14. DOI:10.1038/embor.2012.55. PMID 22565320. https://doi.org/10.1038/embor.2012.55
  • Lawinger P. et al. The neuronal repressor REST/NRSF is an essential regulator in medulloblastoma cells. Nature Med. 2000; 6:826-831 https://doi.org/10.1038/77565
  • Fuller G. N. et al. Many human medulloblastoma tumors over express repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16. Mol. Cancer Ther. 2005; 4:343-349
  • Su X. et al. Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol. Cell. Biol. 2006; 26:1666-1678. https://doi.org/10.1128/MCB.26.5.1666-1678.2006
  • Majumder S. REST in good times and bad: roles in tumor suppressor and oncogenic activities. CellCycle. 2006; 5:1929-1935. https://doi.org/10.4161/cc.5.17.2982
  • Mik G., Gholve P.A., Scher D.M., Widmann R.F., Green D.W. Down syndrome: orthopedicissues. Curr Opin Pediatr. 2008; 20(1):30-6. https://doi.org/10.1097/MOP.0b013e3282f35f19
  • Loane M., Morris J.K., Addor M.C. et al. (January 2013). «Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening». Eur. J. Hum. Genet. 21(1):27-33. https://doi.org/10.1038/ejhg.2012.94
  • Frost A.E., Quinones M.A., Zoghbi W.A., Noon G.P. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol. J. Heart. Lung Transplant. 2005; 24(4):501-503. https://doi.org/10.1016/j.healun.2004.02.004
  • Vida V.L., Barnoya J., Larrazabal L.A., Gaitan G., de Maria Garcia F., Castaneda A.R. Congenital cardiac disease in children with Down's syndrome in Guatemala. Cardiol Young. 2005; 15:286-90 https://doi.org/10.1017/S1047951105000582
  • Galie N., Humbert M., Vachiery J.L., Gibbs S., Lang I. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2015; 1-58
  • Schwerzmann M., Zafar M., McLaughlin P.R., Chamberlain D.W., Webb G., Granton J. Atrial septal defect closure in a patient with 'irreversible' pulmonary hypertensive arteriopathy. Int. J. Cardiol. 2006; 110(1):104-107.20. https://doi.org/10.1016/j.ijcard.2005.05.062
  • Balling G, Gildein HP, Genz T, Kaemmerer H, Hess J. Transcatheter closure of a non-restrictive patent ductusarteriosuswith an Amplatzer muscular ventricular septal defect occluder. Int.JCardiol. 2007; 117(1):e40-e42.
  • Dimopoulos K., Peset A., Gatzouulis M.A. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int.J.Cardiol. 2008; https://doi.org/10.21693/1933-088X-6.3.126
  • Yamauchi H., Yamaki S., Fujii M., Iwaki H., Tanaka S. Reduction in recalcitrant pulmonary hypertension after operation for atrial septal defect. Ann Thorac. Surg. 2001; 72(3):905-906 https://doi.org/10.1016/S0003-4975(00)02537-6
  • Huang J.B., Liu Y.L., Yu C.T., Lv X.D., Du M., Wang Q. et al. Lung iopsy findings in previously inoperable patients with severe pulmonary hypertension associated with congenital heart disease. Int. J. Cardiol. 2011; 151(1):76-83. https://doi.org/10.1016/j.ijcard.2010.04.094
  • Galie N., Beghetti M., Gatzoulis M.A., Granton J., Berger R.M., Lauer A. et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114(1):48-54. https://doi.org/10.1161/CIRCULATION AHA.106.630715
  • Budts W., Van Pelt N., Gillyns H., Gewillig M., Van de Werf F., Janssens S. Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome. Heart. 2001; 86(5):553-558.37. https://doi.org/10.1136/heart.86.5.553
  • Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 2004; 351(14):1425-1436. https://doi.org/10.1056/NEJMra040291
  • Novick W.M., Sandoval N., Lazorhysynets V.V., Castillo V., Baskevitch A., Mo X. et al. Flap valve double patch closure of ventricular septal defects in children with increased pulmonary vascular resistance. Ann.Thorac.Surg. 2005; 79(1):21-28 https://doi.org/10.1016/j.athoracsur.2004.06.107
  • Larios R., Fitch E.A., Blanco G., Bailey C.P. The use of an artificial foraminal valve prosthesis in the closure of interatrial and interventricular septal defects. Dis Chest. 1959; 36:631-41. https://doi.org/10.1378/chest.36.6.631
  • Liu Y.L., Hu S.S., Shen X.D., Li S.J., Wang X., Yan J. et al. Midterm results of arterial switch operation in older patients with severe pulmonary hypertension. Ann. Thorac.Surg. 2010; 90(3):848-855.
  • Huang J.B., Liu Y.L., Yu C.T., Lv X.D., Du M., Wang Q. et al. Lung biopsy findings in previously inoperable patients with severe pulmonary hypertension associated with congenital heart disease. Int. J. Cardiol. 2011; 151(1):76-83. https://doi.org/10.1016/j.ijcard.2010.04.094
  • Epting C.L., Wolfe R.R., Abman S.H., Deutsch G.H., Ivy D. Reversal of Pulmonary Hypertension Associated with Plexiform Lesions in Congenital Heart Disease: A Case Report. Pediatr. Cardiol. 2002; 23(2):182-185. https://doi.org/10.1007/s00246-001-0044-9
  • Ohashi N., Matsushima M., Maeda M., YamakiS. Two-Stage Procedure for Pulmonary Vascular Obstructive Disease in Down Syndrome With Congenital Heart Disease. Circ. J. 2006; 70:1446-1450 https://doi.org/10.1253/circj.70.1446